Back

An autoantibody-based machine learning classifier for the detection of early-stage non-small cell lung cancer

Kung, A. F.; Didigu, C. A.; Wang, C.-Y.; Saxena, A.; Castillo-Rojas, B.; Mitchell, A. M.; Mann, S. A.; Murillo, A.; Zorn, K. C.; Bod, L.; Jablons, D. M.; Kratz, J. R.; DeRisi, J. L.

2025-01-10 oncology
10.1101/2025.01.09.24315050 medRxiv
Show abstract

The humoral immune system plays a significant role in the immune response to cancer but is challenging to study at scale. We used programmable phage immunoprecipitation sequencing (PhIP-Seq) to profile the autoantibody repertoire in non-small cell lung cancer (NSCLC) patients for the purpose of training a machine learning-based classifier to distinguish NSCLC patients from healthy controls using 301 primarily early-stage, asymptomatic NSCLC patients and 352 healthy controls. The classifier performed well in cross-validation (average ROC-AUC = 0.94) and in an independently analyzed clinical validation cohort of 134 NSCLC patients and 96 healthy controls (ROC-AUC = 0.84). Classification performance can be maintained with only a few hundred target peptides, provided a sufficiently large cohort is used for optimal training. Our findings suggest the existence of a measurable autoreactive humoral profile in NSCLC and demonstrate the potential for serum-based early detection of cancer independent of nucleic acids.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.